$32.44
-0.41[-1.25%]
At close: Apr 19
$32.44
0[0.00%]
After Hours: 4:00PM EDT
Tarsus Pharmaceuticals
(NASDAQ:TARS)Tarsus Pharmaceuticals Stock (NASDAQ:TARS), Analyst Ratings, Price Targets, Predictions
Tarsus Pharmaceuticals Inc has a consensus price target of $49.75, established from looking at the 22 latest analyst ratings. The last 3 analyst ratings were released from Jefferies, Goldman Sachs, and HC Wainwright & Co. on March 6, 2024, February 29, 2024, and February 28, 2024. With an average price target of $43.67 between Jefferies, Goldman Sachs, and HC Wainwright & Co., there's an implied 34.61% upside for Tarsus Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Goldman Sachs
HC Wainwright & Co.
Barclays
Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Tarsus Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/06/2024 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 35.64% | Jefferies | Anthony Petrone | $30 → $44 | Maintains | Buy | Get Alert |
| 02/29/2024 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | -7.52% | Goldman Sachs | Andrea Tan | $19 → $30 | Maintains | Neutral | Get Alert |
| 02/28/2024 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 75.71% | HC Wainwright & Co. | Oren Livnat | $50 → $57 | Maintains | Buy | Get Alert |
| 02/28/2024 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 54.13% | Barclays | Balaji Prasad | $40 → $50 | Maintains | Overweight | Get Alert |
| 02/28/2024 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 81.87% | Oppenheimer | Francois Brisebois | $55 → $59 | Reiterates | Outperform → Outperform | Get Alert |
| 11/20/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | -41.43% | Goldman Sachs | Andrea Tan | → $19 | Initiates | → Neutral | Get Alert |
| 11/10/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 54.13% | HC Wainwright & Co. | Oren Livnat | $42 → $50 | Maintains | Buy | Get Alert |
| 09/11/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 51.05% | Guggenheim | Eddie Hickman | $46 → $49 | Maintains | Buy | Get Alert |
| 08/14/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 41.8% | Guggenheim | Eddie Hickman | → $46 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 29.47% | HC Wainwright & Co. | Oren Livnat | $50 → $42 | Maintains | Buy | Get Alert |
| 07/26/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 54.13% | HC Wainwright & Co. | Oren Livnat | $44 → $50 | Maintains | Buy | Get Alert |
| 07/18/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 35.64% | William Blair | — | → $44 | Initiates | → Outperform | Get Alert |
| 06/26/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 35.64% | HC Wainwright & Co. | Oren Livnat | $40 → $44 | Maintains | Buy | Get Alert |
| 06/16/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 29.47% | Guggenheim | Eddie Hickman | $40 → $42 | Maintains | Buy | Get Alert |
| 05/18/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | — | Guggenheim | Eddie Hickman | — | Initiates | → Buy | Get Alert |
| 05/08/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 32.55% | Oppenheimer | Francois Brisebois | → $43 | Reiterates | → Outperform | Get Alert |
| 03/15/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 23.3% | HC Wainwright & Co. | Oren Livnat | → $40 | Reiterates | → Buy | Get Alert |
| 08/01/2022 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 23.3% | Barclays | Balaji Prasad | → $40 | Initiates | → Overweight | Get Alert |
| 12/21/2021 | TARS | Buy Now | Tarsus Pharmaceuticals | $32.44 | 23.3% | HC Wainwright & Co. | Oren Livnat | → $40 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Tarsus Pharmaceuticals (TARS)?
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Jefferies on March 6, 2024. The analyst firm set a price target for $44.00 expecting TARS to rise to within 12 months (a possible 35.64% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tarsus Pharmaceuticals (TARS)?
The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ: TARS) was provided by Jefferies, and Tarsus Pharmaceuticals maintained their buy rating.
When was the last upgrade for Tarsus Pharmaceuticals (TARS)?
There is no last upgrade for Tarsus Pharmaceuticals.
When was the last downgrade for Tarsus Pharmaceuticals (TARS)?
There is no last downgrade for Tarsus Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Tarsus Pharmaceuticals (TARS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on March 6, 2024 so you should expect the next rating to be made available sometime around March 6, 2025.
Is the Analyst Rating Tarsus Pharmaceuticals (TARS) correct?
While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a maintained with a price target of $30.00 to $44.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $32.44, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.